.@PCF_SELECT #cfDNA assay detects #allelicimbalance (e.g. BRCA2, ATM, PTEN) in #prostatecancer plasma with high sensitivity. Consortium of @FrancescaBZNY @AttardLab @mishabeltran @ResearchWyatt @MarkARubin1 labs and teams! @PCF_Science @AIRC_it @CR_UK academic.oup.com/narcancer/a…

The #IPCS26 @APCCC_Lugano with wonderful data in #prostatecancer 1️⃣Liquid biopsies 2️⃣Neuroendlcrine differentiation 🔵Epigenetics 🔴NEMO: Neuroendocrine monitoring panel 🟢Targeting methylation @Silke_Gillessen @mishabeltran @DanaFarberNews @RodRogSan @feresparza06

Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair response genes PPM1D, TP53, ATM, and CHEK2. ■ Clinical significance unclear but may become more relevant as radioligand therapy moves into earlier lines of treatment @ResearchWyatt @AzadOncology

Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich Please follow ecancer.org/en/video/12526-b…

Just out today in @jclinicalinvest 🚀 mHSPC is not one disease, but a kaleidoscope of biological states. We highlight what we know — and the key gaps that remain — on the road to precision medicine✨ Led by my mentor @mishabeltran 🙌 #ProstateCancer #mHSPC #PrecisionOncology

Excited to share our new paper @NatureComms in collaboration with @RickmanLab, led by #RichaSingh @WeillCornell and @Bajji @DanaFarber #BeltranLab

Understanding ctDNA technology applications for cancer detection and characterization. @ResearchWyatt @VanProstateCtr joins @UroDocAsh @MDAndersonNews to break down the fundamentals of cell-free DNA and how ctDNA represents the tumor-derived portion of these fragments in the bloodstream. #WatchNow on UroToday > bit.ly/42EeUm4

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer @NatureComms rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab @DanaFarber_GU @PCF_Science

Favorite study! Germline-somatic tandems dictate cancer subtypes, provide clinical insights, and fuel molecularly informed studies. Kudos: Blerta Stringa, @Paola_Gasperini, Alessandro Alaimo, and @LunardiLabCIBIO (co-last a!) @NimaSharifiMD doi.org/10.1158/2159-8290.CD… @UniTrento

Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative biomarkers (SUVmean) are additive 🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire Online at @NatureMedicine nature.com/articles/s41591-0… @ANZUPtrials #TheraP @MovemberAUS @PCFA Support by @PCF_Science Challenge Award @ResearchWyatt @AzadOncology @Prof_IanD

Elegant presentation from @ResearchWyatt on the evolution of ctDNA detection and characterization! Session chaired by @DanaFarber_GU's @OncoBellmunt and @BartsECMC 's @b_szabados #GU25 @ASCO @OncoAlert @OncLive

Exciting work ahead on Large #Oncosomes at the @UniTrento @CIBIO_UniTrento with our team #DemichelisLab, Dolores Di Vizio @doldivizio at @CedarsSinai and Shannon Stott @svploeg at @MGH_RI funded by the @theNCI #PLUS

Proud of our LIG1 loss/PARP inhibition #SL study in @jclinicalinvest by @GiuliaFracassi_ an @AIRC_it fellowship awardee and @FraLo05 a @PCF_Science YIA Collaborators: @quimmateo @FdAdF66 Relevant to #prostatecancer and beyond. Download it! jci.org/articles/view/179393

PROSTATE Paper 2 Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostate cancer using plasma cell-free DNA with an AUC > 0.93. Their assay also quantifies tumor content and offers a phenotype evidence score, which reflects various CRPC phenotypes. @CD_AACR . Lead our own @mishabeltran @DanaFarber_GU aacrjournals.org/cancerdisco…

Heartbroken💔we lost Dr. Felix Feng— close friend, selfless collaborator, brilliant scientist & a man who saved many prostate cancer lives with a triad of generosity, kindness, & teamwork. We miss you @felixfengmd --too early my friend. To all: please consider supporting this @ASTRO_org @AmericanCancer award in Felix name: donate.cancer.org/g/tjjfqwdn…?

Felix was the best of us. I'm heartbroken by his passing.💔His spirit of generosity, kindness, humility, his humor, intelligence & scientific acumen - you made us better scientists & better people, Felix. Love & miss you always. My deepest condolences to @MaryFengMD & family.🙏♥️

The last time Felix stood on our stage, after a beautiful talk by @mishabeltran & intro by @AminaZoubeidi 💔💔💔 vimeo.com/1037583309/b7dd022…

A tremendous loss for the cancer scientific community. @felixfengmd truly was one of the very best. I feel fortunate to have had the chance to meet him. This is heartbreaking but I want to remember him with the smile that always lit up his face 💔@MaryFengMD 💔

Exciting news! Dr. Alex Wyatt, a senior research scientist at the Vancouver Prostate Centre, is now the scientific director for the Clinical Cancer Genomics Program at BC Cancer. @ResearchWyatt prostatecentre.com/news/dr-a…

@mishabeltran sharing DLL3 PET/CT images including correlation with PSMA and FDG from @morr316 @PCF_Science TACTICAL grant #ESMO24 @myESMO